Optiver Holding
GALT icon

Optiver Holding’s Galectin Therapeutics GALT Stock Holding History

Optiver Holding’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$566 Buy
122
+104
+578% +$270 ﹤0.01% 2561
2026
Q1 		$50 Hold
18
– – ﹤0.01% 2262
2025
Q4 		$75 Hold
18
– – ﹤0.01% 2384
2025
Q3 		$76 Buy
+18
New +$68 ﹤0.01% 2608

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Optiver Holding's GALT Position: Q2 2026 in Review

Optiver Holding increased its Galectin Therapeutics (GALT) stake by 578% in Q2 2026, buying an estimated $270 and bringing the position to 122 shares worth $566. The position accounts for ﹤0.01% of the portfolio, ranked #2561.

Optiver Holding first reported a position in GALT in Q3 2025 and has held it in 4 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Optiver Holding held 122 shares of Galectin Therapeutics worth $566 as of Q2 2026.
  • Optiver Holding bought 104 Galectin Therapeutics shares in Q2 2026, an estimated $270.
  • Galectin Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2561 holding.
  • Optiver Holding first reported a position in Galectin Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.